Cargando…
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients
OBJECTIVES: To further validate the diagnostic utility of (18)F-AV-133 vesicular monoamine transporter type 2 (VMAT2) positron emission tomography (PET) in patients with clinically uncertain parkinsonian syndromes (CUPS) by comparison to clinical diagnosis at 3 years follow-up. DESIGN, SETTING AND P...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252699/ https://www.ncbi.nlm.nih.gov/pubmed/30446576 http://dx.doi.org/10.1136/bmjopen-2018-025533 |
_version_ | 1783373323926765568 |
---|---|
author | Xu, San San Alexander, Paschal K Lie, Yenni Dore, Vincent Bozinovski, Svetlana Mulligan, Rachel S Young, Kenneth Villemagne, Victor L Rowe, Christopher C |
author_facet | Xu, San San Alexander, Paschal K Lie, Yenni Dore, Vincent Bozinovski, Svetlana Mulligan, Rachel S Young, Kenneth Villemagne, Victor L Rowe, Christopher C |
author_sort | Xu, San San |
collection | PubMed |
description | OBJECTIVES: To further validate the diagnostic utility of (18)F-AV-133 vesicular monoamine transporter type 2 (VMAT2) positron emission tomography (PET) in patients with clinically uncertain parkinsonian syndromes (CUPS) by comparison to clinical diagnosis at 3 years follow-up. DESIGN, SETTING AND PARTICIPANTS: In a previous study, we reported that (18)F-AV-133 PET in community patients with CUPS changed diagnosis and management and increased diagnostic confidence. The current diagnosis of this cohort was obtained from the patient and treating specialist and compared with the diagnosis suggested 3 years earlier by the (18)F-AV-133 PET. A second (18)F-AV-133 PET was available in those with a discordant or inconclusive final diagnosis. STUDY OUTCOME MEASURES: The primary end point was the proportion of patients who had a follow-up clinical diagnosis, which was concordant with their initial (18)F-AV-133 PET scan. Secondary end points were the proportion of patients who had the same diagnosis at follow-up as that reached after the initial scan and the stability of diagnostic changes made after the first scan. RESULTS: 81 of the 85 patients previously recruited to the CUPS study had follow-up of which 79 had a clinical diagnosis and 2 remained CUPS. The diagnosis was in agreement with the initial (18)F-AV-133 PET scan result in 74 cases. Five patients had a discordant diagnosis; one patient with rubral tremor had a severely abnormal scan that had worsened when rescanned; four cases with normal initial and repeat scans had a clinical diagnosis of Parkinson’s disease. Two patients with suspected genetic disorders remained classified as CUPS and both had normal scans. In the 24 CUPS cohort patients where (18)F-AV-133 PET initially changed diagnosis, this change was supported by follow-up diagnosis in all but the one rubral tremor case. CONCLUSION: (18)F-AV-133 PET is a useful tool in improving diagnostic accuracy in CUPS providing results and diagnostic changes that remain robust after 3 years follow-up. |
format | Online Article Text |
id | pubmed-6252699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62526992018-12-11 Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients Xu, San San Alexander, Paschal K Lie, Yenni Dore, Vincent Bozinovski, Svetlana Mulligan, Rachel S Young, Kenneth Villemagne, Victor L Rowe, Christopher C BMJ Open Neurology OBJECTIVES: To further validate the diagnostic utility of (18)F-AV-133 vesicular monoamine transporter type 2 (VMAT2) positron emission tomography (PET) in patients with clinically uncertain parkinsonian syndromes (CUPS) by comparison to clinical diagnosis at 3 years follow-up. DESIGN, SETTING AND PARTICIPANTS: In a previous study, we reported that (18)F-AV-133 PET in community patients with CUPS changed diagnosis and management and increased diagnostic confidence. The current diagnosis of this cohort was obtained from the patient and treating specialist and compared with the diagnosis suggested 3 years earlier by the (18)F-AV-133 PET. A second (18)F-AV-133 PET was available in those with a discordant or inconclusive final diagnosis. STUDY OUTCOME MEASURES: The primary end point was the proportion of patients who had a follow-up clinical diagnosis, which was concordant with their initial (18)F-AV-133 PET scan. Secondary end points were the proportion of patients who had the same diagnosis at follow-up as that reached after the initial scan and the stability of diagnostic changes made after the first scan. RESULTS: 81 of the 85 patients previously recruited to the CUPS study had follow-up of which 79 had a clinical diagnosis and 2 remained CUPS. The diagnosis was in agreement with the initial (18)F-AV-133 PET scan result in 74 cases. Five patients had a discordant diagnosis; one patient with rubral tremor had a severely abnormal scan that had worsened when rescanned; four cases with normal initial and repeat scans had a clinical diagnosis of Parkinson’s disease. Two patients with suspected genetic disorders remained classified as CUPS and both had normal scans. In the 24 CUPS cohort patients where (18)F-AV-133 PET initially changed diagnosis, this change was supported by follow-up diagnosis in all but the one rubral tremor case. CONCLUSION: (18)F-AV-133 PET is a useful tool in improving diagnostic accuracy in CUPS providing results and diagnostic changes that remain robust after 3 years follow-up. BMJ Publishing Group 2018-11-15 /pmc/articles/PMC6252699/ /pubmed/30446576 http://dx.doi.org/10.1136/bmjopen-2018-025533 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Neurology Xu, San San Alexander, Paschal K Lie, Yenni Dore, Vincent Bozinovski, Svetlana Mulligan, Rachel S Young, Kenneth Villemagne, Victor L Rowe, Christopher C Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title | Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title_full | Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title_fullStr | Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title_full_unstemmed | Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title_short | Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients |
title_sort | diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (vmat2) in clinically uncertain parkinsonian syndrome (cups): a 3-year follow-up study in community patients |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252699/ https://www.ncbi.nlm.nih.gov/pubmed/30446576 http://dx.doi.org/10.1136/bmjopen-2018-025533 |
work_keys_str_mv | AT xusansan diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT alexanderpaschalk diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT lieyenni diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT dorevincent diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT bozinovskisvetlana diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT mulliganrachels diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT youngkenneth diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT villemagnevictorl diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients AT rowechristopherc diagnosticaccuracyofimagingbrainvesicularmonoaminetransportertype2vmat2inclinicallyuncertainparkinsoniansyndromecupsa3yearfollowupstudyincommunitypatients |